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Summary Intravascular ultrasound imaging has been pivotal in the understanding of coronary
artery disease and the development of percutaneous coronary intervention. The ability to anal-
yse vessel walls and measure atherosclerotic lesions more accurately has enabled the ﬁeld of
invasive cardiology to overcome the limits of angiography. In fact, intravascular ultrasound mea-
surements correlate with functional measurement of coronary blood ﬂow, as a result interest in
their use for the diagnosis of lesion severity in ambiguous lesions and for left main trunk analysis
has grown. On the interventional side, intravascular ultrasound is used to determine the major
predictors of restenosis and stent thrombosis, which are the main pitfalls of percutaneous coro-
nary intervention. In the bare-metal stent era, intravascular ultrasound-guided percutaneous
coronary intervention was associated with a reduction in restenosis rates because it enabled
identiﬁcation and treatment of the risk factors for complications. Although drug-eluting stents
have provided a great technological advance in percutaneous coronary intervention, further
reducing the rate of in-stent restenosis, they have not abolished restenosis completely; intravas-
cular ultrasound has also been used in this setting to identify the mechanisms responsible for
drug-eluting stent restenosis. As in the bare-metal stent era, identiﬁcation of the predictors
of restenosis and stent thrombosis and their subsequent treatment may offer the promise of
improved outcome in the drug-eluting stent era. This review focuses on the potential beneﬁt of
intravascular ultrasound-guided percutaneous coronary intervention with regard to restenosis
and stent thrombosis in the bare-metal stent and drug-eluting stent eras.
© 2009 Published by Elsevier Masson SAS.
∗ Corresponding author. Fax: +202 877 2715.
E-mail address: ron.waksman@medstar.net (R. Waksman).
1875-2136/$ — see front matter © 2009 Published by Elsevier Masson SAS.
doi:10.1016/j.acvd.2008.11.002
144
MOTS CLÉS
Échographie
endovasculaire ;
Cathétérisme
inteventionnel
coronaire,
angioplastie
coronaire ;
Endoprothèse, stent
coronaire
coronaire. Cette revue vise à résumer les données relatives au bénéﬁce potentiel de l’utilisation
de l’échographie endocoronaire pour guider l’angioplastie coronaire sur la resténose et la
thrombose de stent dans l’ère des stents métalliques et ceux des stents actifs.
© 2009 Publie´ par Elsevier Masson SAS.
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Dbbreviations
AD coronary artery disease
MS bare-metal stents
ES drug-eluting stents
VUS intravascular ultrasound
ACE major adverse cardiac events
LA minimum luminal stent area
LD minimum luminal diameter
CI percutaneous coronary intervention
ES paclitaxel-eluting stents
ES sirolimus-eluting stents
T stent thrombosis
LR target lesion revascularization
ntroduction
VUS has played a critical role in the development of inter-
entional cardiology. The superior imaging capabilities of
VUS compared with angiography have increased our under-
tanding of the pathophysiology of coronary atherosclerosis
remendously and have enabled signiﬁcant reﬁnements to
e made to the diagnosis and percutaneous treatment of
AD. More than 10 years after its ﬁrst use in humans, IVUS is
till a key research tool in the ﬁeld of medical treatment and
ercutaneous revascularization for CAD patients. Interest in
VUS has also grown in clinical practice, for both diagnosis
nd intervention. Indeed, because of its higher spatial reso-
ution and the fact that it enables analysis of the insides of
essel walls, IVUS provides a more reproducible and accu-
ate measurement of disease severity than angiography [1].
VUS measurements have been correlated with functional
q
l
l
s
tow data, which has allowed this anatomical device to be
sed to diagnose ﬂow-limiting lesions accurately [2]. Fur-
hermore, in the era of BMS, IVUS helped to implement stent
elivery procedures and optimize implantation [3]. Studies
upported a potential beneﬁt of IVUS-guided PCI compared
ith angiography-guided PCI in this era, through a reduction
n restenosis, although this remains controversial [4—10].
The advent of DES, which decreased the rate of in-stent
estenosis dramatically, may reduce the potential impact of
VUS [11]. However, intimal hyperplasia is not abolished by
he use of DES and has been linked to stent under-expansion,
alapposition and incomplete lesion coverage by IVUS [12].
n addition, recent data suggest that IVUS use may prevent
T after implantation of DES [13]. Furthermore, studies
ave shown that in a high proportion of cases of early ST,
VUS enabled identiﬁcation of a mechanical abnormality
hat may have been responsible for the event [14]. Whether
he identiﬁcation and subsequent treatment of the risk fac-
ors for in-stent restenosis and early ST make IVUS-guided
CI clinically beneﬁcial compared with angiography-guided
CI in the DES era remains a topic for debate. We aim to
eview the potential clinical beneﬁt of IVUS-guided PCI in
he DES era by assessing available data.
VUS as a diagnostic tool
espite being the ‘‘gold standard’’ for assessing andL. Bonello et al.
Résumé L’imagerie par échographie endovasculaire a joué un rôle déterminant dans la
compréhension de la coronaropathie et dans le développement de l’angioplastie coronaire.
La possibilité d’analyser la paroi vasculaire et de mesurer de fac¸on plus précise les lésions
athéromateuses ont permis à la cardiologie interventionnelle de dépasser les limites de
l’angiographie. En effet, les mesures réalisées à l’aide de l’échographie endocoronaire sont
corrélées avec la mesure du ﬂux sanguin coronaire et présente donc un intérêt particulier pour
la mesure de la sévérité des lésions considérées comme angiographiquement ambiguës ou pour
l’évaluation des troncs coronaire gauches. Du point de vue interventionnelle, l’échographie
endocoronaire a permis d’identiﬁer les principaux prédicteurs de resténose et de thrombose
de stent qui représentent les deux principales limitations de l’angioplastie coronaire. Du
fait de sa capacité à identiﬁer les facteurs de risques de ces complications et de permettre
leur traitement, l’angioplastie guidée par l’échographie endocoronaire à l’ère des stents
métalliques était associée à une réduction de la fréquence de la resténose. Les stents actifs
représentent une innovation technologique très importante en angioplastie, permettant
de réduire de considérablement la fréquence de la resténose. Cependant ils ne l’ont pas
aboli et l’échographie endocoronaire à une nouvelle fois permis d’identiﬁer les mécanismes
responsables de cette complication lors de l’utilisation de ces stents dits actifs. Tout comme
dans l’ère des stents métalliques, l’identiﬁcation de ces prédicteurs et leur traitement dans
l’ère des stents actifs pourraient offrir une occasion d’améliorer le pronostic de l’angioplastieuantifying CAD, coronary angiography only provides a
uminography, with little or no data on the vessel’s wall, thus
imiting the ability to detect atheroma and determine lesion
everity. IVUS provides information about vessel walls and
he pathological process taking place in CAD. Consistently,
IVUS-guided PCI 145
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wFigure 1. Illustration of the superiority of IVUS over angiograph
ambiguous lesion with less than 50% stenosis. Right panel: IVUS mea
studies have shown large inter- and intra-observer variabil-
ity in the assessment of lesion severity based on coronary
angiography, even when quantitative coronary angiography
measurements were used [15,16]. In contrast, IVUS imaging
technology has a high spatial resolution (100—200m com-
pared with 0.15—0.25mm for angiography), which allows
accurate measurement of vessel dimension and analysis of
vessel walls, including plaque burden, calciﬁcations and
ﬁbrotic tissue [17,18]. Furthermore, studies have shown a
strong correlation between IVUS measurements and physio-
logical ﬂow assessment using fractional ﬂow reserve evalua-
tion [2]. IVUS can therefore be used reliably and accurately
to determine lesion severity and functional signiﬁcance.
These properties are critical in high-risk lesions such as
left main trunk lesions, where angiography has had mixed
results [19,20]. It must be acknowledged, however, that this
correlation is limited to large arteries (diameter > 3mm2).
In addition, studies have shown consistently that IVUS can
improve the assessment of angiography-intermediate lesions
greatly, by discriminating between those that require inter-
vention and those that do not (Fig. 1) [21].
IVUS as an interventional device
As discussed previously, IVUS has a high spatial resolution
and, together with lumen imaging, facilitates the assess-
ment of a vessel’s wall. These abilities may be of great
value in guiding PCI. In theory, stent implantation could be
optimized with IVUS guidance to prevent the mechanical
issues associated with restenosis and ST.
IVUS to reduce restenosis
Bare-metal stent eraSuboptimal stent expansion results in a reduced stent cross-
sectional area on IVUS and is a stronger predictor of
restenosis after implantation of BMS than any angiographic
variable [22]. In light of these ﬁndings, several studies aimed
to determine whether optimizing stent implantation using
i
S
t
Merms of assessing the severity of coronary lesions. Left panel: an
ment of the same lesion demonstrates a ﬂow-limiting lesion.
VUS is clinically beneﬁcial because of a resultant reduction
n the rate of in-stent restenosis.
The ﬁrst study reported was a multicentre comparison of
VUS-guided and angiography-guided PCI for matched lesions
n = 173 and 173, respectively) [4]. A beneﬁt was seen in
he ‘‘early phase’’ of the study when the IVUS group had
ore aggressive post-dilation with large balloons (six-month
ngiographic restenosis 9.2% vs 22.3%; p = 0.04). However,
o difference was seen in six-month angiographic restenosis
n the ‘‘late phase’’ of the study, when a less aggressive
ost-dilatation approach was used because of a change in
he deﬁnition of optimal stent expansion (22.7% vs 23.7%;
= 1.0). Although this was a non-randomized, observational
tudy, it provided the ﬁrst evidence that IVUS-guided stent
mplantation may result in a different treatment strategy
nd improved clinical outcomes.
Thereafter, small prospective studies conﬁrmed the
uperiority of IVUS guidance over angiographic guidance
n PCI, with a reduced restenosis rate at six-month
ngiographic follow-up. The REStenosis after IVUS-guided
tenting (RESIST) study was the ﬁrst randomized trial to
nvestigate the impact of IVUS-guided PCI on outcome [10].
lthough underpowered, with only 155 patients included,
his study showed a trend toward less angiographic resteno-
is at six-month follow-up in the IVUS-guided PCI group.
oreover, IVUS use resulted in a larger stent lumen cross-
ectional area, which persisted at six-month follow-up.
his study supported the hypothesis that IVUS-guided PCI
s potentially beneﬁcial with regard to in-stent restenosis.
hese results were conﬁrmed by Blasini et al., who showed
signiﬁcant reduction in the rate of angiographic restenosis
t six months with IVUS (20.9% vs 29.9%; p = 0.03); the differ-
nce was particularly evident in patients who fulﬁlled IVUS
riteria for optimal stent placement compared with those
ho did not (13.5% vs 28.3%; p = 0.04) [5].
After these promising early reports, some larger stud-es were performed. The Can Routine Ultrasound Inﬂuence
tent Expansion (CRUISE) study was a prospective, multicen-
re, case-control study with 499 patients [6]. The immediate
LD and MLA obtained by quantitative coronary angiogra-
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sis were a minimum stent area of 5.5mm2 and a stented
length of 40mm (Fig. 2). A similar ﬁnding was reported in
an IVUS study of 33 lesions with DES failure (26 in-stent
restenoses) [25]. Investigators found a minimum stent cross-46
hy were signiﬁcantly larger in the IVUS group. Improved
tent expansion with IVUS guidance resulted in a clinical
eneﬁt at nine-month follow-up in terms of target ves-
el revascularization (8.5% vs 15.3%; p < 0.05). Despite the
ack of randomization, this study was —at that time— the
argest report comparing IVUS-guided stent implantation
ith angiography-guided stent implantation and conﬁrmed
he hypothesis that stent implantation optimization with
VUS guidance is associated with a clinical beneﬁt in terms
f reducing revascularization without impacting death or
yocardial infarction. However, despite great interest in
VUS-guided PCI, these preliminary studies were either not
andomized or had a small sample size.
The OPTimization with IVUS to reduce stent restenosis
OPTICUS) study was a large, randomized study that aimed
o determine if IVUS guidance could reduce the rate of
n-stent restenosis [7]. The primary endpoints were angio-
raphic restenosis rate, MLD and percentage stenosis at six
onths, while the secondary endpoint was the rate of MACE
t six and 12months. This study failed to demonstrate a
igniﬁcant difference in any of the prespeciﬁed endpoints.
he investigators concluded that there was no advantage
o IVUS-guided BMS implantation. A lack of clinical beneﬁt
ith IVUS-guided PCI was also observed in a retrospective
nalysis performed by the Mayo Clinic [9]. In the wake of
he controversy surrounding the potential beneﬁt of IVUS
fter this disappointing study, the device failed to gain wide
cceptance in clinical practice.
The Thrombocyte activity evaluation and effects of
ltrasound guidance in Long Intracoronary stent Placement
TULIP) study was a randomized study comparing IVUS-
uided and angiography-guided stent implantation in long
esions (> 20mm) [8]. IVUS-guided stent implantation was
hown to be beneﬁcial in patients considered to be at high
isk of in-stent restenosis. Despite a small sample size, sig-
iﬁcant reductions in both TLR (10% vs 23%; p = 0.02) and
ACE (12% vs 27%; p = 0.03) were seen at 12-month follow-up
ith IVUS-guided PCI.
Overall, these studies have failed to determine clearly
hether IVUS-guided PCI can reduce in-stent restenosis
ffectively in the BMS era. This may be related to the
act that the ﬁndings of IVUS studies, such as the role of
igh-pressure inﬂation in preventing stent under-expansion
which plays a key role in restenosis), were integrated con-
inuously in clinical practice, thus reducing the potential
eneﬁt of IVUS. However, despite the continuous improve-
ents in PCI technique, IVUS-guided PCI was associated with
t least a trend towards a clinical beneﬁt in most studies and
ay therefore be beneﬁcial for high-risk lesions.
rug-eluting stent era
ES are superior to BMS in terms of rate of restenosis
nd subsequent repeat revascularization procedures [9,11].
espite these major advantages, restenosis is not abolished
nd TLR rates reach 10% at two-year follow-up [22]. The
ncreasing use of DES in complex patient and lesion subsets
as led to signiﬁcantly higher rates of DES restenosis than
hose seen in the randomized studies [23]. Given the encour-
ging results of IVUS-guided PCI in the BMS era, attempts
ere made to expand these ﬁndings in the DES era.
F
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aL. Bonello et al.
Stent under-expansion has been reported consistently as
he predominant mechanism underlying DES restenosis. In
act, neointimal suppression achieved with DES has pro-
oted stent under-expansion as the prime mechanism for
estenosis [12]. In a study of 449 patients (543 lesions) who
ompleted six-month angiographic follow-up after implan-
ation of SES, post-procedural minimum stent area and
tented length on IVUS emerged as the only predictors of DES
estenosis [24]. IVUS cut-off values that predicted resteno-igure 2. Predictors of angiographic restenosis after implanta-
ion of SES. Sensitivity and speciﬁcity curves identify a minimum
tent area of 5.5mm2 and a stented length of 40mm as the cut-
ffs predictive of restenosis on IVUS measurement (from Hong et
l. [24]).
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sectional area of less than 5.0mm2 in 67% of restenosis
cases. In an IVUS study of SES implanted for restenosis, 82%
of DES failures had a post-procedural minimum stent area
less than 5.0mm2 versus 26% in the control group (p = 0.003)
[26]. Signiﬁcant differences were also seen between groups
when comparisons were made for cross-sectional areas of
3 and 4mm2. These studies suggest strongly that there is a
relationship between smaller minimum stent cross-sectional
area and DES restenosis. Conversely, the larger the post-
procedural minimum stent cross-sectional area, the lower
is the likelihood of restenosis. Similar ﬁndings have been
reported for PES and zotarolimus-eluting stents.
Inadequate lesion coverage has also been shown to be a
cause of DES restenosis. In an IVUS substudy of SIRIUS, the
edges of 167 stents were studied [27]. From this cohort, 18
edge stenoses were identiﬁed at eight-month angiographic
follow-up. An association was seen between edge resteno-
sis in the SES group and both larger reference plaque area
and larger stent edge area: reference minimum lumen area
ratio. These ﬁndings suggest that inadequate plaque cov-
erage led to edge stenosis, which could have been avoided
by IVUS guidance. Stent fracture leading to localized drug
under-dosing has been proposed as a mechanism leading to
focal DES restenosis [28]. More research is required to quan-
tify this relationship. It is unlikely that IVUS at the time of
the index procedure would help to prevent this complication
of DES implantation. An IVUS study has also shown non-
uniform stent expansion to be associated with SES restenosis
[29]. This particular study measured stent expansion by
using inter-strut angles and counting stent struts. Though
the measurement of such variables is not practical during
routine IVUS-guided stent implantation, the ﬁndings do high-
light the importance of achieving uniform stent expansion.
Few reports have been published in the DES era
comparing clinical outcomes in patients undergoing IVUS-
guided or angiography-guided stent implantation. In a small
observational study of 58 patients undergoing elective DES
implantation for unprotected left main lesions, no major dif-
ference in clinical outcomes was seen between IVUS-guided
and angiography-guided PCI [30]. Another prospective study
investigated the potential beneﬁcial clinical impact of IVUS-
guided PCI in high-risk lesion and patient subsets in the
DES era [31]. To ensure adequate IVUS use, a target min-
imal stent lumen area of 5mm2 was to be obtained in
this group. This study showed no difference between IVUS-
guided PCI and angiography-guided PCI. Although the author
acknowledged the small sample size, the rates of MACE
at 18months were similar. In this study, IVUS guidance
was associated with higher inﬂation pressure (16.4± 1.7 vs
15.7± 1.5; p < 0.001) and balloon diameter (3.1± 1.1mm
vs 3.3± 0.4mm; p < 0.001) although similar MLDs were
achieved at the end of the procedure in both groups
(2.87± 0.24mm vs 2.94± 0.31mm; p =NS). The TLR and
MACE rates were identical (6% vs 6%; p = 1.0 and 12% vs 11%;
p = 0.7).IVUS to reduce acute and subacute ST
Apart from target vessel revascularization, another major
drawback of PCI that could be improved by IVUS-guided PCI
is ST. In fact, subacute ST was an initial major limitation of
e
I
w
C
t147
MS implantation, with an incidence of 10—15% [32,33]. Dual
ntiplatelet therapy with aspirin and thienopyridine [34—36]
nd high-pressure stent deployment [37] have decreased the
ate of post-PCI thrombotic events signiﬁcantly to an inci-
ence of 0.9% in the modern BMS era [38]. The ﬁrst IVUS
tudy reporting IVUS predictors of subacute ST observed
based on 19 patients) that smaller lumen dimension was an
nivariate predictor and that post-procedural dissection was
multivariable predictor [39].
Predictors and Outcomes of ST (POST) is a multicen-
re registry that aimed to investigate the role of IVUS
n predicting ST compared with angiography [14]. The
tudy included patients who presented with ST after IVUS-
uided PCI. At least one abnormal IVUS ﬁnding (stent
nder-expansion, malapposition, inﬂow/outﬂow disease,
issection or thrombus) was present in 94% of the 53 patients
tudied. Angiographic abnormalities were detected in only
2% of patients. These results suggest that IVUS is supe-
ior to angiography during stent implantation for identifying
eatures associated with ST. Similarly, our institution has
eported the presence of abnormal post-procedural IVUS
ndings in 78% of 23 patients presenting with subacute ST
40]. Reduced lumen dimensions (< 80% reference), dissec-
ion, thrombus and tissue protrusion through stent struts
ere the major IVUS abnormalities associated with ST. These
ndings suggested that subacute ST after BMS implantation
as associated with mechanical causes that could be iden-
iﬁed by IVUS. Although no study has investigated whether
outine use of IVUS can affect the rate of subacute ST in the
MS era, the hypothesis is that IVUS identiﬁcation of abnor-
alities associated with ST and their subsequent treatment
ay result in a reduction in subacute ST. In addition to sub-
cute ST, two other limitations of DES implantation are late
nd very late ST, the mechanisms of which are ill-deﬁned
nd may differ from the mechanical causes of subacute ST.
Reports questioning the safety of DES compared with
MS in terms of increased rates of non-fatal myocardial
nfarction and death have been refuted by meta-analyses
f long-term follow-ups of randomized controlled trials
41—43]. However, a recent study by Daemen et al. reported
constant ST rate of 0.6% per annum, which may be
elated to delayed re-endothelialization [44,45]. There are
ew data on IVUS ﬁndings in patients re-presenting with
ES thrombosis. In a study to identify IVUS predictors of
arly ST, 15 patients presenting with ST after successful
ES implantation were compared with 45 matched con-
rols; stent expansion and reference segment stenosis were
ound to be independent predictors of thrombosis [46]. Sim-
lar ﬁndings have been reported from our institution. In a
ase-control study, 13 patients presenting with DES throm-
osis were compared with 27 matched patients [47]. A
maller stent minimum cross-sectional area (4.6± 1.1mm2
s 5.6± 1.7mm2, p < 0.05) was observed in patients with ST.
n addition, these patients had a larger proximal reference
laque burden (66± 8% vs 56± 10%; p = 0.002).
There are few published data on IVUS ﬁndings in patients
ith late ST. The mechanisms of late ST are likely to be
ven more multifactorial than those of subacute ST, hence
VUS ﬁndings at the index procedure may not correlate
ith these late events. In a monocentre, case-control study,
ook et al. observed a high prevalence of stent malapposi-
ion in patients presenting with very late ST (> 12 months)
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signiﬁcantly (Fig. 3).
The reductions in restenosis achieved with DES may
reduce the impact of routine IVUS guidance on revascu-
larization rates. In our propensity score-matched analysis48
48]. In this study, the IVUS ﬁndings of 13 patients who
resented with ST were compared with a control group
f 144 patients. The groups had similar reference segment
ross-sectional areas but the very late ST group had a sig-
iﬁcantly larger in-stent cross-sectional area. The incidence
f incomplete stent apposition was 77% in the very late ST
roup versus 12% in the control group (p < 0.001). Although
t lacked IVUS data on the index procedure, this study
ighlighted the importance of achieving satisfactory stent
pposition at baseline, irrespective of whether the cases in
he study were persistent or late. A later monocentre study
f 82 patients observed that stent malapposition after DES
mplantation occurred frequently (12%) and did not report
ny link between this ﬁnding and late outcomes as measured
y MACE at 10-month follow-up [49]. Although the rela-
ionship between stent malapposition and late thrombosis
emains controversial, IVUS guidance at the index procedure
an negate malapposition at baseline, which may, in turn,
ave a favourable impact on late ST.
We reported recently a potential beneﬁt of routine
VUS guidance in preventing subacute ST after implanta-
ion of DES [13]. From a registry of unselected patients
ndergoing DES implantation, those who had IVUS-guided
CI were identiﬁed and compared with those undergoing
ngiography-guided PCI (n = 884 in both groups). Propensity-
core matching (considering patient demographics, clinical
haracteristics and presentation, and angiographic features)
as used to compare outcomes. There were signiﬁcant
eductions in subacute ST (0.5% vs 1.4%; p = 0.045) and
umulative ST (0.7% vs 2.0%; p = 0.014) at 12months in the
VUS-guided group. There were trends toward less probable
T and less TLR at 12months in the IVUS-guided group, but
here was no advantage in terms of MACE. The use of IVUS
esulted in signiﬁcant differences in treatment strategy (less
rimary stenting, greater use of rotational atherectomy,
onger stent lengths and more post-dilation). These results
uggest that routine IVUS guidance can detect and result in
ubsequent treatment of the mechanical causes responsi-
le for subacute ST. The failure of routine IVUS guidance to
mpact late events is consistent with the less important role
hat mechanical causes play in late ST.
otential clinical beneﬁt of IVUS guidance
n DES implantation
he important roles of stent under-expansion, malapposi-
ion and lesion coverage in DES restenosis and thrombosis,
nd the ability of IVUS-guided PCI to prevent these events,
upports the hypothesis that IVUS is beneﬁcial in this setting.
To quantify the degree of under-expansion seen with
ES, a study comparing IVUS-determined and compliance
hart-predicted minimum stent diameter and area was per-
ormed [50]. In this study, 133 patients were treated with
ES and 67 patients received PES. Comparison of the indi-
idual types of DES was then made with their respective
MS platforms. DES achieved 75± 10% of predicted mini-
um stent diameter and 66± 17% of predicted minimum
tent area. There were no signiﬁcant differences in the val-
es between DES types. Moreover, 24% of SES and 28% of
ES did not achieve a minimum stent area of 5mm2 (the
alue predictive of restenosis). No difference was seen in
F
i
aL. Bonello et al.
tent expansion between the individual stent types and their
espective BMS platforms. From this ﬁnal observation the
nvestigators concluded that the polymer coating does not
nterfere with DES expansion. A similar ﬁnding was reported
ith BMS, hence the disparity between IVUS measurements
f stent expansion and compliance chart values is not unique
o DES [51]. A study from our institution compared stent
xpansion between SES (n = 46) and PES (n = 42) with serial
VUS [52]. Even at high pressure inﬂations (20 atm), 48 and
5% of stents appeared to be under-expanded in the SES
nd PES groups, respectively. These studies suggest strongly
hat there is discordance between IVUS measurements of
tent expansion and those predicted by compliance charts.
oreover, the studies highlight the need for high-pressure
tent deployment and the importance of IVUS guidance
n ensuring optimal stent deployment. Lesion coverage is,
s described above, a strong predictor of edge restenosis.
VUS-guided PCI has the potential for accurate lesion length
easurement, allowing for adequate coverage and thereby
reventing edge restenosis.
Finally, it may be beneﬁcial to ensure full stent-vessel
all apposition, although this is of less importance than
tent under-expansion and lesion coverage. In fact, stent
alapposition may lead to inadequate drug delivery and
ES failure, and has been associated with late ST. As men-
ioned previously, a recent study performed in our institution
as highlighted the potential beneﬁt of IVUS-guided PCI
ith regard to ST. In this retrospective study, a strong
rend toward less TLR was also seen with IVUS (5.1% vs
.2%; p = 0.07). In another analysis from our institution,
ngiographic and procedural predictors of ST after DES
mplantation were identiﬁed [53]. This was a lesion-based
nalysis of 45 lesions re-presenting with ST compared with
620 unselected lesions that were free of ST at 12months.
ack of IVUS guidance was the only modiﬁable correlate of
T in this analysis (OR 0.45, 95%CI 0.24—0.84; p = 0.013).
s in our previous analysis, IVUS guidance was associated
ith reductions in early ST but failed to affect late eventsigure 3. Kaplan-Meier curves comparing freedom from ST dur-
ng one-year follow-up in patients who had IVUS-guided PCI or
ngiography-guided PCI (from Roy et al. [13]).
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comparing patients undergoing IVUS with those undergo-
ing angiography-guided DES implantation, there was a trend
towards reduced TLR with IVUS (5.1% vs 7.2%; p = 0.06).
In addition, we have identiﬁed lack of IVUS guidance as a
predictor of clinical restenosis (OR 0.68, 95%CI 0.48—0.97;
p = 0.035) [54]. These reduced revascularization trends are
consistent with the role of stent under-expansion in DES
restenosis and the potential beneﬁt of its prevention using
IVUS-guided PCI.
Speciﬁc patient and lesion subsets
Because DES are associated with low rates of events post-
implantation, IVUS-guided PCI may be more relevant in high-
risk patient or lesion subsets. Accordingly, diabetes mellitus
and renal failure, which have been associated with increased
rates of restenosis, may be interesting clinical indications.
Furthermore, lesion subsets with high rates of restenosis or
thrombosis (such as left main disease, bifurcations, ostial
lesions, long lesions, small vessels or restenotic lesions) may
beneﬁt from the use of IVUS. Seung et al. have investigated
the impact of IVUS guidance on left main trunk PCI with SES.
IVUS guidance was used in 86% of the 102 patients included
and the minimal stent area was 9.6± 2.6mm2. The one-year
TLR rate was 2%, which is well below what is usually reported
for such lesions [55].
Limits to the potential beneﬁt of
IVUS-guided PCI
The lack of a proper study demonstrating the beneﬁts
of IVUS-guided PCI may be explained by the fact that
angiography-guided PCI has been updated according to the
knowledge gained by the use of IVUS. PCI has been optimized
according to IVUS ﬁndings and may explain the difﬁcul-
ties in demonstrating a clinical beneﬁt of IVUS-guided PCI.
This explains why IVUS-guided PCI is under-used despite
the fact that the technology has been available for more
than 10 years. Other limits are the cost associated with the
device, although if it is clinically beneﬁcial, then it may
actually be cost-effective. Thus, IVUS may be best-suited
for use with intermediate- or high-risk lesions where it can
be used for both diagnosis and intervention.
Conclusion
IVUS is superior to angiography for determining lesion
severity and is thus warranted in left main, ostial and
intermediate lesion assessment to better quantify lesion
severity. During intervention, IVUS has several potential
advantages, enabling accurate choice of stent diameter
and length or the need for rotational atherectomy. How-
ever, despite these advantages and although a trend toward
improved prognosis with IVUS-guided PCI was found in the
BMS era, the results are less convincing in the DES era.
Although the role of routine IVUS guidance in DES implan-
tation remains uncertain, given the advantages mentioned
previously, its use could lead to clinical beneﬁt in high-risk
patients.
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